|
Market Closed -
London S.E.
11:35:16 2026-08-25 EDT
|
5-day change | 1st Jan Change | ||
| 12,476.00 GBX | +3.02% |
|
+5.68% | -9.53% |
| 08-25 | Melrose soars and stocks climb as oil price cools | AN |
| 08-25 | European Equities Mostly Higher in Tuesday Trading; Equinor Plans Higher Output Outside Norway | MT |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 263,837 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -8.33% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 283,163 | 275,489 | 266,984 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -9.01% | -2.71% | -3.09% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 21.9x | 19x | 16.5x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 4.89x | 4.34x | 3.69x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.2x | 1.3x | 1.1x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 4.17x | 3.95x | 3.7x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.48x | 4.12x | 3.75x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 12.8x | 11.3x | 9.99x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 13.5x | 11.8x | 10.4x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 30.1x | 21.2x | 18.5x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.33% | 4.71% | 5.42% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.339 | 3.561 | 3.662 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 1.96% | 2.09% | 2.15% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.774 | 8.934 | 10.31 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 43% | 39.9% | 35.5% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,250 | 66,839 | 71,270 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,145 | 24,280 | 26,737 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,047 | 23,260 | 25,555 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 12,022 | 13,688 | 15,668 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 19,326 | 11,652 | 3,147 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 170.10 | 170.10 | 170.10 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,024 | - | - |
| Announcement Date | 2/10/22 | 2/9/23 | 2/8/24 | 2/6/25 | 2/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.88x | 4.48x | 12.79x | 1.96% | 264B | |
| 35.12x | 12.73x | 25.81x | 0.56% | 1,100B | |
| 30.38x | - | - | 1.97% | 658B | |
| 33.92x | 7.84x | 16.3x | 2.58% | 470B | |
| 20.83x | 4.94x | 12.23x | 2.67% | 372B | |
| 22.71x | 5.84x | 14.47x | 2.73% | 304B | |
| 27.97x | 7.21x | 12.8x | 2.28% | 239B | |
| 13.99x | 4.96x | 10.35x | 3.67% | 213B | |
| -45.46x | 6.56x | 25.6x | 2.22% | 184B | |
| 17.9x | 3.38x | 8.62x | 6.03% | 163B | |
| Average | 17.93x | 6.44x | 15.44x | 2.67% | 396.57B | |
| Weighted average by Cap. | 25.00x | 8.17x | 18.06x | 2.06% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
